Progenics Pharma (PGNX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
OCCI, IPX, ALZN, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.33 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- RMX Industries signs GPU purchase order with Technologent
- Rithm Capital earns S&P upgrade to ’B+’ following steady revenue diversification
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
